In vivo targeting of dendritic cells (DC) represents an attractive alternative to currently applied ex vivo DC-based genetic tumor vaccination protocols. Finding the optimal vector for in vivo targeting of DC is important for such strategies. We therefore tested a panel of subgroup C/B chimeric and fi ber-modifi ed adenoviruses (Ad) for their relative capacity to transduce human DC. We made use of in vitro generated Langerhans Cells (LC) as well as of ex vivo human skin and melanoma-draining lymph node (LN) derived DC. Of the tested viruses the C/B-chimeric Ad5/3 virus most effi ciently transduced in vitro generated LC. In addition, Ad5/3 preferentially targeted mature myeloid DC from human skin and draining LN and transduced them at signifi cantly higher frequencies than Ad5. In addition, Ad5/3 was more specifi c for mature human skin-derived CD1a + CD83 + DC than the previously reported DC-transducing C/B-chimeric vector Ad5/35, infecting less bystander cells. It was previously reported that Ad5/3 transduced human monocyte-derived DC by binding to the B7 molecules CD80 and CD86. High-effi ciency transduction of mature skin-derived DC was similarly shown to be mediated through binding to CD80/CD86 and not to interfere with subsequent T cell priming.
Introduction
Dendritic cells (DC) are a promising target for gene therapeutic strategies to induce anti-tumor responses, as DC initiate immune responses by presenting tumor associated antigens (TAA) to naïve T cells. Therapeutic strategies that target DC should aim for high transduction effi ciency and specifi city, as optimal TAA delivery to DC is critical for the therapeutic effi cacy of DC-based vaccination strategies. Adenovirus (Ad)-based therapies are ideal for in vivo targeting and infection of DC, as adenoviruses can infect non-replicating cells and can be genetically modifi ed to express a TAA of choice. It is well known that the commonly used subgroup C adenovirus serotype 5 (Ad5) is of limited utility for transduction of human DC, both in vitro and in vivo, as DC lack expression of the adenovirus binding receptor CAR (Coxsackie-and Adenovirus Receptor). Other Ad types without pre-existent immunity and with a natural tropism for DCassociated molecules may be more readily translated to the clinic as vaccination vehicles, without a further need for genetic modifi cation of their fi ber knob to enable DC targeting [1] [2] [3] .
We previously showed more effective skin DC targeting using the subgroup B2 virus Ad35 or a chimeric Ad5/35 virus containing the Ad5 fi ber and Ad35 knob 4 . This virus enters cells via CD46 5, 6 , which is a complement regulatory molecule, present on many cells including DC 7 . Although Ad5/35 was shown to be superior over Ad5 in terms of DC transduction, a more specifi c and truly DC-targeted virus might be preferable, as CD46 is expressed ubiquitously in the skin.
Infection, and subsequent antigen presentation on MHC class I molecules by other cells than professional antigen-presenting cells (APC), might result in sub-effi cient T cell activation, or even T cell anergy or tolerance induction, as a strong co-stimulatory signal via CD80 and CD86
is required to fully activate T cells. We therefore aimed to fi nd a more DC-specifi c adenovirus with high-effi ciency infection characteristics for future in vivo DC-targeting strategies. Short et al. previously reported on the binding of the subgroup B1 adenovirus Ad3 to the co-stimulatory molecules CD80 (B7.1) and CD86 (B7.2) on human monocyte-derived DC (MoDC) 8 . Since expression of these markers is abundant on activated DC, we set out to investigate whether a virus containing the Ad3 knob domain would effectively transduce human skin DC in situ.
The skin presents a readily accessible and highly effi cient conduit for the delivery of Ad-based vaccines and subsequent activation of specifi c T cells 4, 9 . Specialized DC subsets line both the epidermis (i.e. Langerhans Cells [LC] ) and the dermis, which, upon transduction and appropriate activation, can induce TAA-specifi c T cell responses in the draining lymph nodes (LN) 10 . A panel of genetically modifi ed adenoviruses was therefore analyzed for their relative capacity to infect in vitro cultured LC and interstitial (dermal) DC. Amongst these were three different subgroup C/B chimeras, i.e. Ad5/3, Ad5/11 and Ad5/35 as well as three fi ber modifi ed viruses i.e. Ad5.RGD 11 , Ad5.pK7 and Ad5.RGD.pK7 12 . The RGD motif binds integrins and the pK7 polylysine motif can bind heparin sulfate containing receptors 12 . Replication defi cient Ad5 virus was employed for comparison. The most effi cient in vitro transduction was observed with Ad5/3 and Ad5.RGD, in addition to the previously reported Ad5/35. Ad5/3, and not Ad5.
RGD, was found to enhance transduction of DC in the context of intact skin in human explant cultures. Confl icting data were previously reported on the tropism of Ad3 (a B1-type virus):
whether it binds cells primarily via the costimulatory molecules CD80 and CD86 8 IU/ml sodium-penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 50 μM β-mercaptoethanol (2ME) (complete IMDM) and 100 ng/ml recombinant human granulocyte colony stimulating factor (rhGM-CSF) (Sagramostim, Berlex) and 10 ng/ml interleukin-4 (IL-4) (R&D systems) for 5-6 days.
The acute myeloid leukaemia cell line MUTZ3 was cultured in Minimum essential medium-α (MEM-α) (Lonza, Verviers, Belgium) containing 20 % FCS, 100 IU/ml sodium-penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 50 μM 2ME and 10 % conditioned medium of the 5637 renal cell carcinoma cell line (MUTZ3 routine medium) in 12-well plates (Costar) at a concentration of 0.2 million cells/ml and were passaged twice weekly as described 17 . MUTZ3-LC were cultured by seeding MUTZ3 precursor cells in 12-well plates at 0.1 million cells/ml in MEM-α supplemented with 20 % FCS, 100 IU/ml sodium-penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 50 μM 2ME (complete MEM-α). Differentiation medium contained 100 ng/ ml rhGM-CSF, 10 ng/ml TGFβ1 (Biovision, Mountain View, CA) and 120 IU/ml TNFα (Miltenyi Biotec) and cells were differentiated into immature LC for 9-10 days 18 . Immature MoDC and MUTZ3-LC were matured by adding a maturation cocktail containing 2400 IU/ml TNFα, 100 ng/ml IL-6 (R&D systems), 25 ng/ml IL-1β (Miltenyi Biotec) and 1 μg/ml prostaglandin E2 (PGE2) (Sigma Aldrich) for 2 days.
HEK-293 cells (Microbix, Toronto, Canada) and QBI-293A cells (Qbiogene, Heidelberg, Germany) were maintained in Dulbecco's modifi ed Eagle's medium (DMEM) (Lonza, Verviers, Belgium), supplemented with 10 % FCS and 100 IU/ml sodium-penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine. Dermal skin sheets were incubated in collagenase (200 mg collagenase diluted in 26.6 ml PBS and 6.6 ml dispase II) for 90 minutes at 37 o C. Single cell suspensions were made by fi ltering twice through 100 μm sterile fi lters. Viable cells were counted by trypan blue exclusion. Skin single cell suspensions, taken up in IMDM with 5 % human pooled serum (HPS), 100 IU/ml sodium-penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine, were activated with 100 ng/ ml GM-CSF and 10 ng/ml IL-4 in T75 culture fl asks for 24 hours prior to Ad infection.
Human sentinel LN single cell suspensions were prepared as described previously 21 . In short, LN were cut in half. From one half, 10 scrapes were made with a scalpel, rinsing the blade after each scrape in a tube fi lled with 15 ml of 0.1 % DNase and 0.14 % collagenase A (Roche Nederland B.V., Woerden, The Netherlands). The cell suspension was then transferred to a sterile fl ask in a total volume of 30 ml DNase/collagenase, after which the suspension was 
In vitro Ad transduction
In vitro generated MoDC, MUTZ3-LC, or GM-CSF + IL-4 activated skin single cell suspensions were in vitro transduced with the indicated adenoviruses at a MOI of 1000 viral particles (Vp) or 
Transduction of mature DC in human skin and LNs
In situ Ad transduction of human skin DC 6 mm human skin biopsies, pre-activated with GM-CSF and IL-4, were injected with 1x10 9 Vp of Ad5.eGFP, Ad5/35.eGFP or Ad5/3.eGFP in a total volume of 10 μl as described previously 22 .
Cells were allowed to migrate from the biopsies for 48 hours, after which they were harvested, quantifi ed by trypan blue exclusion and fl owcount fl uorospheres, and analyzed for eGFP expression and DC marker expression by fl ow cytometry. 
Mixed leukocyte reaction (MLR)

IL-12 and IL-10 production
Immature MoDC were matured with a maturation cocktail containing 2400 IU/ml TNFα, 100 ng/ml IL-6 and 25 ng/ml IL-1β for 8 hours before Ad transduction (MOI 100 based on IU). For IL-10 and IL-12 secretion, 40,000 control or Ad-transduced DC were co-cultured with 40,000 irradiated CD40L-expressing J558 cells. Supernatants were harvested 24 hours after coculture and were analyzed for IL-12 and IL-10 [IL-10 ELISA kit, Sanquin, The Netherlands] secretion by ELISA following manufacturer's guidelines or as described previously 18 .
Statistical analysis
The paired two-tailed student's T-test was used for statistical analysis, except for analysis of DC-targeting indices, where a non-parametric analysis was used instead (two-tailed Wilcoxin)
due to a lack of a normal distribution. Differences were considered statistically signifi cant when p<0.05.
Results
In vitro cultured DC are effi ciently transduced by subgroup C/B chimeric-and RGDmodifi ed viruses
Seven replication-defi cient adenoviruses (Ad) with embedded distinct tropism profi les were analyzed for their capacity to infect LC, as the major skin-resident DC subset. To compare the data with the C/B chimeras, luciferase expression was used as reporter assay.
An isogenic Ad5 with double-reporter genes was included as a control for the RGD and pK7
viruses (data not shown). 
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Transduction of mature DC in human skin and LNs
The type C/B chimeras gave higher transgene expression levels than Ad5 in LC, with the highest levels in mature LC (mLC) (Fig. 1A ). Ad5/3 infection was specifi cally more effective in mLC than in iLC (p<0.002 for iLC vs mLC and p<0.003 compared to mLC transduction levels by Ad5/11 or Ad5/35). Viruses containing the RGD motif only showed enhanced transduction effi ciency compared to Ad5 in immature LC (iLC) (p<0.004). No advantage was observed with the pK7 insert alone or in combination with RGD, compared to Ad5 infectivity of iLC or mLC. Similar results were obtained with in vitro cultured interstitial DC (IDC) generated from human monocytes (data not shown). Based on the fact that they induced signifi cantly higher transgene levels compared to Ad5, Ad5.RGD and Ad5/3 were selected for further studies.
To study the percentage of infected DC in conjunction with DC surface marker expression, enhanced GFP (eGFP)-encoding Ad5 and Ad5/3 viruses were constructed for further studies.
Ad5.RGD and Ad5/3 were analyzed for their capacity to target and transduce human skin DC in situ compared to Ad5 control viruses. Intra-dermal (i.d.) injection of Ad5.RGD did not enhance the percentage of GFP-positive migrated human skin DC compared to injection of Ad5. In contrast, i.d. injection of Ad5/3 resulted in a marked enhancement of the transduction effi ciency of migrated human skin DC compared to Ad5. Figure 1B shows the transduction effi ciency ratios for in situ skin DC transduction relative to Ad5 for both Ad5.RGD and Ad5/3 (n=3). In light of its superior performance Ad5/3 was further investigated. A titration with eGFPencoding Ad5 and Ad5/3 (MOI 10-1000) on mature human MoDC showed that also at lower viral concentrations, Ad5/3 was superior over wild type Ad5 ( Figure 1C ) in terms of DC transduction. Enhanced in situ transduction capacity by Ad5/3 over Ad5 was observed, as shown in fi gure 1B. To more closely look at the subsets of DC transduced by Ad5/3 during in situ targeting of human skin explants, we gated either on the total DC population based on scatter profi les, the cells expressing the DC marker CD1a, or the maturation marker CD83 (Fig. 2B ). Additional gating was performed on CD80 and CD86 expressing cells (data not shown). Signifi cantly more eGFP + cells were present after Ad5/3 injection as compared to Ad5 injection within all groups (p<0.05). Figure 2C shows the transgene expression levels in the in situ-transduced migrated skin DC. Although not signifi cantly so (most likely due to inter-experimental variation), transduction of human skin DC with Ad5/3 led to considerably increased transgene expression levels as compared to Ad5 (n=3).
Ad5/3 binds human skin DC primarily via CD80 and CD86
As Ad5/3 was reported to bind the B7 family members CD80 and CD86 on in vitro generated human MoDC 8, 25 , but has also been reported to bind CD46 14, 16 , we decided to examine the targeted surface molecules by Ad5/3 on human skin-DC. MoDC and skin-emigrated DC were incubated with a control-Ig or CTLA4-Ig fusion protein, the latter to prevent CD80 and CD86 binding by the virus. As a control, Ad5/35 was taken along, as this subgroup B virus is believed to transduce MoDC through binding of CD46 26 -although binding to CD80 and CD86 has also been reported 25 . Figure 3A shows control-Ig and CTLA4-Ig binding to mature MoDC. All CD80 molecules were blocked after CTLA4-Ig incubation of MoDC, as a PE-labeled anti-CD80
antibody was unable to bind the cells (Fig. 3B) . In contrast, binding of a PE-labeled anti-CD86
antibody was reduced, but not completely blocked after CTLA4-Ig treatment (Fig. 3B ). In the 
CD83
-population (denoted as "ratio DC/non-DC") are presented. Mean values are indicated. Indices for Ad5/3 were signifi cantly higher than the corresponding indices for Ad5 in the epidermis and for Ad5 and Ad5/35 in the dermis (p<0.04).
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Transduction of mature DC in human skin and LNs reduction) (Fig. 3C) . These data clearly show that Ad5/3 primarily uses CD80 and CD86 to bind human DC, whereas Ad5/35 does not.
Ad5/3 less effi cient but more selective for mature skin DC than Ad5/35 Since Ad5/3, unlike Ad5/35, was shown to bind to the DC-specifi c markers CD80 and CD86 in order to transduce human skin DC (Fig. 3C) , we analyzed whether this infl uenced the selectivity of these viruses for mature DC within human skin single cell suspension. Single cell suspensions were made from dermal or epidermal sheets to investigate the transduction specifi city of Ad5, Ad5/3 and Ad5/35 for the DC populations within human skin. Figure 4A displays the percentages and expression levels of Langerin, CD80, CD86 and CD83 on CD1a + DC within epidermal-and dermal single cell suspensions, twenty-four hours after GM-CSF and IL-4 treatment. These GM-CSF+IL-4 activated, total cell suspensions were in vitro transduced with the different Ads.
Transduction effi ciencies were low for Ad5, whereas both Ad5/3 and Ad5/35 transduced
CD1a
+ DC within the epidermal or dermal cell populations at signifi cantly higher effi ciencies than Ad5 (Fig. 4B, p<0 .05 for both Ad5/3 and Ad5/35 vs. Ad5), in keeping with our previous observations for Ad35 4 . While Ad5/35 in turn was more effi cient in transducing LC and dermal DC than Ad5/3, it was also less specifi c for mature skin DC than Ad5/3, as signifi cantly more (Fig. 4B) . We showed that the Ad5/3 required binding to the co-stimulatory molecules CD80 and CD86 on human skin DC in order to transduce the cells (Fig. 3C ) 8 . In line with this and in conjunction with higher expression levels of CD86 and CD80 on CD1a + DC as compared to CD11c hi CD14 -DC present within the LN (Fig. 5A) , there was a signifi cantly better transduction of CD1a + DC by Ad5/3 (p<0.02) and virtually no transduction of the CD80 -CD86 -immature pDC ( Fig. 5A and 5B). Of note, both Ad5/3 and Ad5/35 transduction of CD1a + DC within the SLN resulted in signifi cantly enhanced transgene expression levels as compared to Ad5-mediated transduction (Fig. 5C ). (Fig. 6C) . Thus, transduction of DC by Ad5/3 through binding of CD80 or CD86 does not hamper DC-induced T cell activation or DC cytokine release.
A5/3-mediated transduction does not alter the T cell stimulatory capacity of skin DC
Discussion
The aim of this study was to examine the applicability of Ad5/3 as a human cutaneous DC- High transduction effi ciency and Ad-binding after retargeting should not interfere with DC functionality. Whereas CD46 surface expression was shown to be down-regulated upon binding of Ad35 30 , transduction with Ad5/3 did not reduce expression levels of CD80 or CD86.
Ad5/3 transduction had no effect on the capacity of the DC to induce T cell proliferation in an allogeneic MLR, whereas CD80/CD86 blockade did, nor on the secreted cytokine profi le of the infected cells. These data thus indicate that Ad5/3 can be used to target mature human DC in situ, while preserving the capacity of the DC to migrate and subsequently stimulate T cells. As Ad5/3 transduced less bystander cells in the skin compared to Ad5/35, there may be a reduced likelihood of causing unwanted side effects, but whether in a therapeutic setting one would benefi t more from a virus with somewhat higher effi ciency but lower specifi city (Ad5/35) or vice versa (Ad5/3) remains to be further examined in relevant in vivo models. Based on data by Ophorst et al., these comparative in vivo studies, or indeed clinical trials, could best be carried out with Ad35-and Ad3-based vaccines rather than the respective Ad5 Fib35 or Fib3 chimeras. They found that an Ad5/35 chimera could not circumvent Ad5-directed pre-existing immunity in vivo in BALB/c mice or non-human primates 36 , whereas there was a far lower prevalence of anti-group B immunity than anti-Ad5 immunity and Ad35-based therapeutic vaccines were not affected by pre-existing anti-Ad5 immunity 37, 38 . Wu et al. showed that replacing the Ad5 hexon with an Ad3 hexon already prevented neutralization in mice with pre-existing anti-Ad5 immunity 39 . In addition, it would be interesting to analyze whether Ad3- as more than one DC-receptor can be targeted simultaneously. Also, with the Ad3 knob having a natural DC-targeting ability without the need for further genetic modifi cation, the generation of molecularly defi ned, clinical-grade batches might be more feasible than with genetically modifi ed DC-targeted viruses (e.g. a previously reported CD40-targeted fi ber mosaic variant 40 ). While more research is warranted, these prime/boost or combinatorial Ad vaccine options could certainly benefi t future immunotherapeutic strategies.
